Highbridge Capital Management LLC Purchases New Holdings in BioAtla, Inc. (NASDAQ:BCAB)

Highbridge Capital Management LLC acquired a new stake in shares of BioAtla, Inc. (NASDAQ:BCAB) in the 4th quarter, HoldingsChannel reports. The firm acquired 2,509,626 shares of the company’s stock, valued at approximately $1,484,000. Highbridge Capital Management LLC owned about 0.05% of BioAtla as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in shares of BioAtla in the fourth quarter valued at approximately $230,000. Magnus Financial Group LLC purchased a new position in BioAtla in the 4th quarter valued at $28,000. Massachusetts Financial Services Co. MA grew its position in BioAtla by 5.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock valued at $1,002,000 after buying an additional 28,133 shares during the last quarter. Finally, XTX Topco Ltd increased its stake in BioAtla by 7.2% in the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after buying an additional 10,384 shares during the period. 77.23% of the stock is owned by institutional investors and hedge funds.

BioAtla Stock Performance

BCAB stock opened at $0.39 on Friday. The stock has a market capitalization of $18.98 million, a PE ratio of -0.23 and a beta of 1.19. The company has a fifty day moving average of $0.41 and a 200-day moving average of $1.14. BioAtla, Inc. has a one year low of $0.24 and a one year high of $4.02.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.